STAFFORDSHIRE, UK--(BUSINESS WIRE)--Biocomposites (www.biocomposites.com) announced today that the company’s unique bone graft substitute geneX®, has been cleared for use by the State Food and Drug Administration (SFDA) of the People’s Republic of China.
